# Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)

> **NCT00239980** · PHASE2 · COMPLETED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 77 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** dalteparin

## Key facts

- **NCT ID:** NCT00239980
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2010-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239980, "Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00239980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*